Advanced Medical Optics bid for Bausch & Lomb runs into troubled waters
This article was originally published in Clinica
Dissident shareholders could scupper Advanced Medical Optics' (AMO) plans to acquire Bausch & Lomb and clear the way for rival bidder Warburg Pincus to claim final victory.
You may also be interested in...
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.